Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Identifieur interne : 000721 ( Ncbi/Merge ); précédent : 000720; suivant : 000722Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Auteurs : Ruth Djaldetti [Israël] ; Rivkah Inzelberg ; Nir Giladi ; Amos D. Korczyn ; Yehudit Peretz-Aharon ; Martin J. Rabey ; Yuval Herishano ; Silvia Honigman ; Sami Badarny ; Eldad MelamedSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Biological Availability, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (pharmacokinetics), Double-Blind Method, Drug Combinations, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (analogs & derivatives), Levodopa (pharmacokinetics), Male, Middle Aged, Neurologic Examination, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , analogs & derivatives : Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Carbidopa, Levodopa.
- Administration, Oral, Adult, Aged, Biological Availability, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neurologic Examination, Treatment Outcome.
Abstract
Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double-blind, levodopa-controlled, multicenter study of oral LDEE solution compared with standard levodopa-carbidopa (LD-CD) tablets. Sixty-two patients with Parkinson's disease who had "delayed on" and "no-on" subtypes of response fluctuations were randomly assigned for treatment with LDEE-CD or LD-CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post-lunch dose of LD were replaced. This was followed by a 2-week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post-lunch dose) in the LDEE-CD group. Percentage of no-on episodes after the post-lunch dose was decreased by 21% in the LDEE-CD group but increased by 36% in the LD-CD group (P < 0.01). In phase B, LDEE-CD decreased latencies to on after the morning and post-lunch doses and no-on episodes after the post-lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no-on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption.
PubMed: 11921115
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B30
- to stream PubMed, to step Curation: 003B30
- to stream PubMed, to step Checkpoint: 003A01
Links to Exploration step
pubmed:11921115Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.</title><author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rabin Medical Center, Petah Tiqva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Petah Tiqva</wicri:regionArea><wicri:noRegion>Petah Tiqva</wicri:noRegion></affiliation></author><author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name></author><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D" last="Korczyn">Amos D. Korczyn</name></author><author><name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name></author><author><name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J" last="Rabey">Martin J. Rabey</name></author><author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name></author><author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name></author><author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11921115</idno><idno type="pmid">11921115</idno><idno type="wicri:Area/PubMed/Corpus">003B30</idno><idno type="wicri:Area/PubMed/Curation">003B30</idno><idno type="wicri:Area/PubMed/Checkpoint">003A01</idno><idno type="wicri:Area/Ncbi/Merge">000721</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.</title><author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rabin Medical Center, Petah Tiqva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Petah Tiqva</wicri:regionArea><wicri:noRegion>Petah Tiqva</wicri:noRegion></affiliation></author><author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name></author><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D" last="Korczyn">Amos D. Korczyn</name></author><author><name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name></author><author><name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J" last="Rabey">Martin J. Rabey</name></author><author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name></author><author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name></author><author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Biological Availability</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (pharmacokinetics)</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (analogs & derivatives)</term><term>Levodopa (pharmacokinetics)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Biological Availability</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double-blind, levodopa-controlled, multicenter study of oral LDEE solution compared with standard levodopa-carbidopa (LD-CD) tablets. Sixty-two patients with Parkinson's disease who had "delayed on" and "no-on" subtypes of response fluctuations were randomly assigned for treatment with LDEE-CD or LD-CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post-lunch dose of LD were replaced. This was followed by a 2-week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post-lunch dose) in the LDEE-CD group. Percentage of no-on episodes after the post-lunch dose was decreased by 21% in the LDEE-CD group but increased by 36% in the LD-CD group (P < 0.01). In phase B, LDEE-CD decreased latencies to on after the morning and post-lunch doses and no-on episodes after the post-lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no-on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11921115</PMID><DateCreated><Year>2002</Year><Month>03</Month><Day>28</Day></DateCreated><DateCompleted><Year>2002</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>297-302</MedlinePgn></Pagination><Abstract><AbstractText>Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double-blind, levodopa-controlled, multicenter study of oral LDEE solution compared with standard levodopa-carbidopa (LD-CD) tablets. Sixty-two patients with Parkinson's disease who had "delayed on" and "no-on" subtypes of response fluctuations were randomly assigned for treatment with LDEE-CD or LD-CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post-lunch dose of LD were replaced. This was followed by a 2-week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post-lunch dose) in the LDEE-CD group. Percentage of no-on episodes after the post-lunch dose was decreased by 21% in the LDEE-CD group but increased by 36% in the LD-CD group (P < 0.01). In phase B, LDEE-CD decreased latencies to on after the morning and post-lunch doses and no-on episodes after the post-lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no-on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Djaldetti</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rabin Medical Center, Petah Tiqva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inzelberg</LastName><ForeName>Rivkah</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Nir</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Korczyn</LastName><ForeName>Amos D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Peretz-Aharon</LastName><ForeName>Yehudit</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rabey</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Herishano</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Honigman</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Badarny</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Melamed</LastName><ForeName>Eldad</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C454359">levodopa ethylester</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11921115</ArticleId><ArticleId IdType="pii">10.1002/mds.10075</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D" last="Korczyn">Amos D. Korczyn</name><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name><name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J" last="Rabey">Martin J. Rabey</name></noCountry><country name="Israël"><noRegion><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000721 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000721 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11921115
|texte= Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11921115" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |